Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study-Reference-Cited by-同舟云学术

Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study

Published:2024-02-08 Issue:4 Volume:103 Page:1197-1209
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Zhao Lei,Yang Jinjun,Chen Mengran,Xiang Xinrong,Ma Hongbing,Niu Ting,Gong Yuping,Chen Xinchuan,Liu Jiazhuo,Wu Yu^ORCID

Funder

National Natural Science Foundation of China

Sichuan Provincial Academic and Technical Support Funding Project

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05646-7.pdf

Reference40 articles.

1. Nagel G, Weber D, Fromm E et al (2017) Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol 96:1993–2003. https://doi.org/10.1007/s00277-017-3150-3

2. Wei AH, Montesinos P, Ivanov V et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135:2137–2145. https://doi.org/10.1182/blood.2020004856

3. Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 30:2670–2677. https://doi.org/10.1200/JCO.2011.38.9429

4. DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7–17. https://doi.org/10.1182/blood-2018-08-868752

5. DiNardo CD, Pratz KW, Letai A et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216–228. https://doi.org/10.1016/S1470-2045(18)30010-X

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

2. Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies;International Journal of Molecular Sciences;2024-06-08